SeaCrest Wealth Management LLC Sells 25,000 Shares of Emergent BioSolutions Inc. (NYSE:EBS)

SeaCrest Wealth Management LLC cut its stake in Emergent BioSolutions Inc. (NYSE:EBS) by 21.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 93,700 shares of the biopharmaceutical company’s stock after selling 25,000 shares during the quarter. SeaCrest Wealth Management LLC’s holdings in Emergent BioSolutions were worth $896,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. B. Riley Wealth Advisors Inc. bought a new position in shares of Emergent BioSolutions in the third quarter valued at about $295,000. Barclays PLC raised its position in shares of Emergent BioSolutions by 361.6% in the third quarter. Barclays PLC now owns 39,308 shares of the biopharmaceutical company’s stock valued at $329,000 after purchasing an additional 30,792 shares during the period. Oak Hill Advisors LP bought a new position in shares of Emergent BioSolutions in the third quarter valued at about $9,296,000. Geode Capital Management LLC raised its position in shares of Emergent BioSolutions by 4.6% in the third quarter. Geode Capital Management LLC now owns 581,958 shares of the biopharmaceutical company’s stock valued at $4,861,000 after purchasing an additional 25,776 shares during the period. Finally, Wellington Management Group LLP raised its position in shares of Emergent BioSolutions by 19.6% in the third quarter. Wellington Management Group LLP now owns 136,289 shares of the biopharmaceutical company’s stock valued at $1,138,000 after purchasing an additional 22,295 shares during the period. 78.40% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on EBS shares. Benchmark increased their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Emergent BioSolutions in a research note on Friday, January 10th. Finally, StockNews.com upgraded shares of Emergent BioSolutions from a “hold” rating to a “buy” rating in a research note on Tuesday.

Emergent BioSolutions Trading Up 1.1 %

EBS stock opened at $9.46 on Thursday. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The company’s 50-day simple moving average is $9.37 and its 200 day simple moving average is $9.18. Emergent BioSolutions Inc. has a 52 week low of $1.42 and a 52 week high of $15.10. The company has a market capitalization of $512.58 million, a PE ratio of -2.31 and a beta of 1.60.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.